

# Validation of the Prognostic Utility of the Electrocardiogram for Acute Drug Overdose

Alex F. Manini, MD, MS; Ajith P. Nair, MD; Rajesh Vedanthan, MD, MPH; David Vlahov, RN, PhD; Robert S. Hoffman, MD

**Background**—While it is certain that some emergency department patients with acute drug overdose suffer adverse cardiovascular events (ACVE), predicting ACVE is difficult. The prognostic utility of the ECG for heterogeneous drug overdose patients remains to be proven. This study was undertaken to validate previously derived features of the initial ECG associated with ACVE in this population.

**Methods and Results**—We performed a prospective validation cohort study to evaluate adult emergency department patients with acute drug overdose at 2 urban university hospitals over 5 years in whom an emergency department admission ECG was performed. Exclusion criteria were alternate diagnoses, anaphylaxis, chronic drug toxicity, and missing outcome data. ACVE was defined as any of the following: circulatory shock, myocardial injury, ventricular dysrhythmia, or cardiac arrest. Blinded cardiologists interpreted ECGs for previously derived predictors of ACVE (ectopy, QT prolongation, nonsinus rhythm, ischemia/infarction), QT dispersion, and prominent R wave in lead AVR. Of 589 patients who met inclusion criteria (48% male, mean age 42), there were 95 ACVEs (39 shock, 64 myocardial injury, 26 dysrhythmia, 16 cardiac arrest). The most common drug exposures were as follows: benzodiazepines, opioids, and acetaminophen. Previously derived criteria were highly predictive of ACVE, with QT correction >500 ms as the highest risk feature (OR 11.2, CI 4.6–27).

**Conclusions**—This study confirms that early ECG evaluation is essential to assess the cardiovascular prognosis and medical clearance of emergency department patients with acute drug overdose. Furthermore, this study validates previously derived high-risk features of the admission ECG to risk stratify for ACVE in this patient population. (*J Am Heart Assoc.* 2017;6:e004320. DOI: 10.1161/JAHA.116.004320.)

**Key Words:** cardiovascular events • electrocardiogram • overdose • poisoning

With nearly 100 deaths per day since 2007, the United States is currently experiencing its worst drug overdose epidemic of all time.<sup>1</sup> The death rate of 11.8 per 100 000-persons in 2007 was roughly 3 times the rate in

1991.<sup>2</sup> Ten to 15% of emergency department (ED) patients with acute drug overdose suffer adverse cardiovascular events (ACVE), but prediction is difficult.<sup>3</sup> In order to curtail the rise in drug overdose mortality,<sup>1,2,4</sup> clinicians must be equipped with valid clinical predictive tools to accurately identify those at risk for morbidity/mortality from the cardiovascular consequences of drug abuse.

In addition to consultation with a regional poison control center or on-site medical toxicologist, routine ED evaluation may include an ECG. We have previously identified characteristics of the initial ECG (ectopy, QT prolongation, nonsinus rhythm, ischemia/infarction) that were associated with ACVE in patients with acute drug overdose.<sup>5</sup> However, the prognostic utility of the ECG for heterogeneous drug overdose patients has not been definitively established.<sup>6</sup>

Therefore, in this study, we aimed to validate previously derived features of the initial ECG associated with ACVE in this population. Additionally, we aimed to calculate the diagnostic test characteristics of specific ECG factors for prediction of ACVE in ED patients with acute drug overdose. We hypothesized the following: (1) high-risk ECG factors will successfully predict ACVE in ED drug overdose patients; (2) test characteristics of the rule will achieve >90% sensitivity

*From the Division of Medical Toxicology, Elmhurst Hospital Center (A.F.M.) and Zena and Michael A. Wiener Cardiovascular Institute (R.V.), The Icahn School of Medicine at Mount Sinai, New York, NY; Section of Cardiology, Baylor College of Medicine, Houston, TX (A.P.N.); Office of the Dean, School of Nursing, University of California, San Francisco, CA (D.V.); Division of Medical Toxicology, Ronald O. Perleman Department of Emergency Medicine, NYU School of Medicine, New York, NY (R.S.H.).*

Preliminary versions of the results were presented in May 2014 at the Society for Academic Emergency Medicine (SAEM) Annual Meeting in Dallas, Texas, and in May 2014 at the 34th International Congress, European Association of Poisons Centres and Clinical Toxicologists (EAPCCT), in Brussels, Belgium.

**Correspondence to:** Alex F. Manini, MD, MS, Department of Emergency Medicine, The Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Pl, Box 1620, New York, NY 10029. E-mail: alex.manini@mssm.edu

Received July 20, 2016; accepted December 1, 2016.

© 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

and specificity; and (3) QT correction (QTc) prolongation will afford highest predictive value.

## Methods

### Study Design and Setting

We performed a secondary data analysis of a prospective cohort study that was previously described.<sup>3,7</sup> The study was conducted at 2 urban, tertiary care adult ED over a 4-year period from 2008 to 2012. The EDs have a combined annual visit volume in excess of 150 000 and are staffed 24 hours per day with board-certified emergency physicians. A medical toxicology consulting service was available if deemed necessary in addition to routine clinical care. The study protocol was approved by the institutional program for the protection of human subjects with waiver of informed consent.

### Study Population

Consecutive, adult ED patients with suspected acute drug overdose were screened 24 hours per day by trained research assistants. Excluded were patients with alternate diagnoses (eg, trauma, sepsis, anaphylaxis), age <18 years, chronic presentations, nondrug toxicity (eg, plants), duplicate ED visits, do-not-resuscitate orders, exposure limited to topical or inhalation, prisoners, and missing/incomplete data (ie, left against medical advice, transferred to an outside institution, or otherwise eloped from the hospital). Eligible patients were included in this analysis if there was performance of an initial ECG within the first hour of ED arrival.

### Data Collection

Data collection from the medical chart occurred in accordance with accepted guidelines for valid medical chart abstraction, including training of abstractors and 95% agreement of a random sampling of 10 test charts prior to mass data abstraction.<sup>8</sup> Medical record data were relied upon for all data measurements, including study outcomes. These data included demographics (sex, age, race), exposure information (timing of exposure, number of exposures, intent, suicidality), toxin identification (detail from history of present illness, serum drug concentrations if available), prior cardiovascular medical history (hypertension, diabetes, coronary artery disease or congestive heart failure), and toxicology screens (urine ELISA panel and serum concentration, if any). Blood and urine toxicology screen results sent as routine part of clinical care (ie, no confirmatory gas chromatography/mass spectrometry) were recorded in order to confirm exposure. Data were abstracted to a de-identified electronic database with password protection.

## Study Outcomes

We used the previously derived definition of ACVE as the primary study outcome, which is outlined in Table 1. For myocardial injury assessment, subjects without a laboratory evaluation of troponin I were assumed to be negative. For ventricular dysrhythmia assessment, rhythm strips in the charts of inpatients receiving telemetry monitoring were reviewed to evaluate any alarmed segments. As an exploratory analysis, we evaluated ECG evidence of ischemia/infarction using myocardial injury alone as a secondary outcome.

### ECG Interpretation

ECGs were performed as clinically indicated according to the standard of care, as previously described.<sup>5</sup> ECGs were interpreted by 2 blinded cardiologists (who were unaware of the diagnosis or whether an ACVE occurred) using de-identified copies of the initial ECG, and using a standard ECG interpretation form, were evaluated for the initial rhythm, intervals, QRS duration, evidence of ischemia/infarction, and QT dispersion (QTD). ECG evidence of ischemia was defined as either T wave inversion or ST depression. ECG evidence of infarction was defined as either ST elevation or Q waves. In addition, the presence of any R wave >3 mm in lead AVR ( $R_{avr}$ ) was documented, as previously described.<sup>9</sup>

### QT Correction

Based on prior experience,<sup>5</sup> the computer-generated corrected QT interval (Bazett's corrected QTc,  $QT/RR^{1/2}$ ) was used because it was exceedingly rare that manual measurements ever substantially changed the QTc value. "QTc prolongation" was defined using standard criteria as  $QTc \geq 470$  ms regardless of sex.<sup>10</sup> Additionally, a "severe QTc" cutoff of  $\geq 500$  ms regardless of sex was evaluated based on prior data suggesting utility of this cut point to predict adverse cardiovascular outcomes.<sup>3,7,11,12</sup>

**Table 1.** Definition of the Primary Study Outcome, ACVE

Outcome	Definition	N*
Myocardial injury	Elevation in cardiac troponin I (>0.09 ng/mL)	64
Shock	Hypotension or hypoperfusion requiring use of a vasopressor	39
Ventricular dysrhythmia	Ventricular tachycardia/fibrillation or torsade de pointes	26
Cardiac arrest	Loss of pulses requiring CPR	16

ACVE indicates adverse cardiovascular events; CPR, cardiopulmonary resuscitation; N, number of patients with individual outcome occurrence in this study.

\*Some patients had more than 1 single outcome.

## QT Dispersion

For the purposes of QTD calculation, QT interval was measured from the beginning of the QRS complex to the end of the T wave (defined as the return to T-P baseline using the threshold method). When U waves were present, the QT interval was measured as the nadir of the curve between T and U waves. QTD was defined as the difference between the longest and the shortest manual raw QT measurement on a 12-lead ECG according to the optimal technique described by Malik and colleagues.<sup>13</sup> To ensure validity of QTD measurements, a random sampling of a subset of ECGs underwent independent interpretation by a second cardiologist; interrater reliability for the QTD cut point (QTD  $\geq$ 35 ms) was assessed on 10 randomly chosen ECGs by 2 independent cardiologists with perfect agreement ( $k=1.0$ ).

## Statistical Analysis

Diagnostic test characteristics (ie, sensitivity, specificity) were calculated for previously derived ECG factors (ectopy, QT prolongation, nonsinus rhythm, and ischemia/infarction). ECG factors were evaluated for prediction of ACVE with  $\chi^2$ ,  $t$  test, odds ratios (OR), and 95% CI. OR of ACVE for dichotomized ECG measures were estimated as measures of effect, and adjusted OR for ECG variables were calculated using multivariable logistic regression adjusting for hypertension, diabetes, and prior coronary disease.

Receiver operating characteristics curves were plotted for QTc and QTD measurements, with optimal cut points chosen that maximized the sum of sensitivity plus specificity. In addition, because ECG evidence of ischemia/infarction may be felt to have a different interpretation in the setting of drug overdose (ie, different clinical picture than patients with chest pain), we assessed whether ECG evidence of ischemia/infarction could predict overdose-related adverse events (ACVE, as well as myocardial injury alone, as defined in Table 1).

In order to determine the number of ECGs needed for cardiologist analysis, the study sample size was calculated a priori. We assumed 10% prevalence of ECG predictor variables, as well as baseline 8% ACVE rate in the population based on prior literature.<sup>3</sup> A clinically meaningful increase in risk was deemed to be a 3-fold increase in odds of ACVE for a given ECG factor. Using these assumptions, we calculated the need to enroll 552 patients with 80% power and 5% alpha.

## Results


### Patient Characteristics

Out of 2378 patients screened during the study period, 1796 were eligible and 589 were included for analysis; complete

study enrollment with inclusion/exclusion criteria are summarized in Figure 1. Compared to those missing an ECG (N=1207), included patients were of similar age (mean age difference 2.6 years), similar sex (48% versus 54% males), and had similar prevalence of coronary artery disease (9% versus 4%), congestive heart failure (5% versus 2%), diabetes (15% versus 13%), and hypertension (28% versus 24%). Of all patients who met inclusion criteria, 48% were male, and the mean age was 42 years. All patients had confirmation of drug exposure either by self-report or serum/urine toxicology. Baseline clinical characteristics of included patients are summarized in Table 2. The most common drug exposures were the following drug classes: benzodiazepines, opioids, and acetaminophen.

### ECG Characteristics of Entire Cohort

Mean heart rate was 87 beats/minute, mean QRS was 90.6 ms, and mean QTc was 439.9 ms. Sinus rhythm was observed in 557 patients (including 117 sinus tachycardia, and 31 sinus bradycardia), 18 atrial fibrillation/flutter, 4 atrioventricular block, 1 supraventricular tachycardia, 1 junctional, and 8 other/unknown. There were 23 patients with ectopy visible on the ECG, and 82 patients with positive  $R_{avr}$ . Interpretation of ischemia/infarction identified 72 patients with evidence of ischemia (55 T-wave inversion, 23 ST depression), and 60 with evidence of infarction (18 ST elevation, 43 Q waves). Regional distributions of ischemia/infarction were as follows: 30 anterior, 41 inferior, 49 lateral,



**Figure 1.** Study enrollment table. ED indicates emergency department.

**Table 2.** Baseline Clinical Characteristics

Clinical Characteristic	ACVE (N=95)	No Events (N=494)
	Mean or %	
Age, y*	53.1	40.4
Female	45	49
Past cardiovascular history		
Hypertension <sup>†</sup>	57	27
Diabetes	27	17
Coronary artery disease <sup>†</sup>	27	6
Congestive heart failure <sup>†</sup>	18	1.5
ECG intervals		
Heart rate, bpm <sup>†</sup>	109	86
QRS, ms <sup>†</sup>	111	90
QTc, ms*	457	437

ACVE indicates adverse cardiovascular events; bpm, beats per minute; N, number of patients; QTc, corrected QT interval.

\* $P<0.001$ .

<sup>†</sup> $P<0.05$ .

13 septal, 4 global/diffuse, 3 nonspecific, and 7 other/unknown.

## Outcomes

There were 95 patients who suffered the primary study outcome (ie, ACVE), with numbers of occurrences of each individual outcome (shock, myocardial injury, ventricular dysrhythmia, and cardiac arrest) listed in Table 1. Some patients had more than 1 individual outcome.

## Main Results

ECG variables and associations with ACVE are summarized in Table 3. All previously derived criteria (ectopy, QTc  $\geq 470$  ms, nonsinus rhythm, any ischemia/infarction) were highly predictive of ACVE. Test characteristics of 2 rules were calculated: (1) those of the previously derived version (ectopy, QTc  $\geq 470$  ms, nonsinus rhythm, and any ischemia/infarction); and (2) new revised criteria utilizing the 4 highest risk factors from this validation study (ectopy, QTc  $\geq 500$  ms, nonsinus rhythm, and any ischemia). The revised criteria substantially improve upon specificity (up by 18.2%) and positive predictive value (up by 16.2%), without sacrificing sensitivity or negative predictive value. The comparison of diagnostic characteristics for the derivation cohort as well as the validation cohort, with original/revised criteria, is summarized in Table 4.

Results of the QT interval analysis are illustrated in Figure 2. Mean QTc was significantly higher in the ACVE

**Table 3.** Presence of ECG Variables and Associated Odds of ACVE

ECG Variables	N	OR (CI)	Adjusted* OR (CI)
QT corrected (QTc)			
Severe $\geq 500$ ms <sup>†</sup>	23	11.2 (4.6–27)	16.1 (6.6–38.8)
Prolonged $\geq 470$ ms <sup>†</sup>	99	2.7 (1.5–4.6)	2.8 (1.7–4.8)
ECG rhythm			
Nonsinus rhythm <sup>†</sup>	29	8.9 (3.9–19.9)	12.8 (4.7–34.8)
Ectopy <sup>†</sup>	23	5.3 (2.2–12.3)	5.2 (1.9–14.3)
Ischemia/infarction			
Ischemia <sup>†</sup>	72	5.0 (2.9–8.5)	3.9 (2.1–7.2)
Infarction <sup>†</sup>	60	2.3 (1.2–4.2)	1.7 (0.8–3.3)
QT dispersion (QTD)			
Severe $\geq 50$ ms <sup>‡</sup>	102	2.2 (1.3–3.7)	2.0 (1.1–3.5)
ROC cut point $\geq 35$ ms <sup>†</sup>	261	3.1 (1.9–4.9)	2.8 (1.7–4.6)
Evidence of Na channel blockade			
R <sub>avR</sub>	82	1.7 (0.98–3.1)	2.0 (1.1–3.7)
QRS $\geq 100$ ms <sup>†</sup>	100	4.4 (2.7–7.1)	4.1 (2.4–7.0)

ACVE indicates adverse cardiovascular events; Na, sodium; OR, odds ratio; R<sub>avR</sub>, R wave  $>3$  mm in lead AVR; ROC, receiver operating characteristics.

\*Adjusted OR for ECG variables were calculated using multivariable logistic regression adjusting for hypertension, diabetes, and prior coronary disease.

<sup>†</sup> $P<0.001$ .

<sup>‡</sup> $P<0.01$ .

group compared with those without events (mean difference +20.0 ms,  $P=0.0004$ ). The optimal QTc cut point based on receiver operating characteristics analysis was QTc  $\geq 500$  ms, which conferred over 11-fold higher odds of ACVE (OR 11.2, CI 4.6–27). Mean QTD was significantly higher in the ACVE group compared with those without events (mean difference +13.8 ms,  $P=0.00018$ ). The optimal QTD cut point based on receiver operating characteristics analysis was QTD  $\geq 35$  ms, which conferred over 3-fold higher odds of ACVE (OR 3.1, CI 2.0–5.0).

Finally, we assessed whether ECG evidence of ischemia/infarction was associated with drug overdose-induced myocardial injury. The results of this analysis are summarized in Table 5. ST elevation had the highest specificity (97.7%), followed by ST depression (97.3%). Any nonsinus rhythm was highly predictive of myocardial injury (OR 11.0,  $P<0.01$ ). Severe QTc prolongation ( $>500$  ms, OR 5.3,  $P<0.001$ ) as well as severe QTD prolongation ( $>50$  ms, OR 2.5,  $P<0.01$ ) were both highly associated with myocardial injury.

## Discussion

This study validates the utility of the ECG for the initial approach to ED patients with acute drug overdose. We found

**Table 4.** Test Characteristics of the ECG Factors as a Prediction Rule for ACVE

	Sensitivity (CI)	Specificity (CI)	NPV (CI)	PPV (CI)	OR (CI)
Derivation cohort*	94.1% (80–99)	49.5% (39–60)	96.2% (87–100)	38.6% (28–50)	1.6 (1.3–1.9)
Validation cohort Original criteria*	68.4% (58–78)	68.6% (64–73)	91.9% (87–94)	29.6% (24–36)	4.7 (2.9–7.6)
Validation cohort Revised criteria†	57.9% (47–68)	86.8% (84–90)	91.5% (89–94)	45.8% (37–55)	4.4 (3.3–5.9)


ACVE indicates adverse cardiovascular events; NPV, negative predictive value; OR, odds ratio; PPV, positive predictive value; QTc, corrected QT interval.

\*Presence of at least 1 of the following: (1) ectopy; (2) QTc ≥470 ms; (3) nonsinus rhythm; (4) ischemia/infarction.

†Presence of at least 1 of the following: (1) ectopy; (2) QTc ≥500 ms; (3) nonsinus rhythm; (4) ischemia.

that previously derived ECG factors, including QT prolongation, rhythm, and presence of ischemia/infarction, were highly predictive of in-hospital ACVE. The test characteristics (eg, sensitivity) of the ECG factors alone were not sufficient enough to exclude the likelihood of ACVE; however, the ECG was highly specific for both myocardial injury and ACVE, with many factors reaching specificity >90%. Therefore, future study should evaluate combining highly sensitive methods (eg, clinical risk scores)<sup>7</sup> with the highly specific tools described within this study.

Many recommendations for the emergency cardiovascular care of poisoned patients are based on expert consensus, rather than scientific evidence.<sup>14</sup> Additionally, because standard guidelines for emergency cardiovascular care may not be optimal for the management of acute poisoning and overdose, urgent consultation with a medical toxicologist or regional poison control center is recommended for patients with cardiovascular toxicity by the American Heart Association, the American Academy of Clinical Toxicology, and the American College of Emergency Physicians.<sup>15</sup> Previously, we defined



**Figure 2.** ROC analysis of QT interval methods for prediction of ACVE. Boxplots for QTD (A) and QTc (B) demonstrate the median (central line), IQR (boxes), range (upper/lower lines), and outliers (circles/asterisks). ROC curves for QTD (C, blue line) and QTc (D, red line) demonstrate the optimal cut points and c statistic (area under the curve). ACVE indicates adverse cardiovascular events; c, area under the curve; QTc, corrected QT interval; QTD, QT dispersion; ROC, receiver operating characteristics.

**Table 5.** Prediction of Myocardial Injury Using ECG Evidence of Ischemia/Infarction

ECG Finding	OR (CI)	Sensitivity	Specificity
<b>Ischemia findings</b>			
ST depression *	6.0 (2.5–14.4)	14.1	97.3
T wave inversion *	4.6 (2.4–8.8)	26.6	92.8
Any ischemia *	6.0 (3.3–10.7)	37.5	90.9
<b>Infarction findings</b>			
ST elevation †	4.4 (1.6–12.2)	9.4	97.7‡
Q waves †	2.8 (1.3–5.9)	15.6	93.7
Any infarction *	3.3 (1.7–6.3)	23.4	91.4
<b>Combined findings</b>			
Any ischemia/infarct *	5.1 (3.0–8.8)	51.4§	82.8

Myocardial injury is defined in Table 1. OR indicates odds ratios.

\* $P < 0.001$ .

† $P < 0.01$ .

‡Highest specificity.

§Highest sensitivity.

in-hospital ACVE as a complication of drug overdose consisting of any of the following: myocardial injury, shock, dysrhythmias, and cardiac arrest.<sup>3</sup> We also previously identified characteristics of the initial ECG (ectopy, QTc  $\geq 470$  ms, nonsinus rhythm, ischemia/infarction) that were associated with ACVE in patients with acute drug overdose.<sup>5</sup> This study adds to this body of literature by confirming and revising these criteria to include the presence of at least 1 of the following: ectopy; QTc  $\geq 500$  ms, nonsinus rhythm, or ischemia.

Drug toxicity may cause myocardial injury through a variety of mechanisms. Myocardial injury is the most common ACVE that occurs because of drug overdose.<sup>3,16</sup> Serum cardiac troponin I is a useful biomarker for drug toxicity.<sup>17–19</sup> According to guidelines from the American Heart Association, the approach to patients with symptoms of drug-induced myocardial injury should differ in both diagnostic and therapeutic management.<sup>14</sup> However, such guidelines currently rely upon expert consensus on the role of the ECG and cardiac biomarkers because of a previous lack of evidence-based tools to risk-stratify and guide management. This study therefore verifies and improves upon these guidelines to optimize the prediction of adverse events in this patient population.

ECG evidence of ischemia or infarction was highly specific for drug-induced myocardial injury. An implication of this study is that early drug cardiotoxicity can be detected by screening for ischemia and infarction, in addition to rhythm and intervals. The strongest predictor of cardiac arrest was ST depression, which conferred over 6-fold increased odds. Unfortunately, the sample size of the present study did not

allow for subgroup analysis of ECG findings for individual or specific drugs; therefore, external validation of these findings is warranted. The combination of the ECG findings coupled with real-time clinical judgment may provide the basis for future implementation studies of these findings. On the basis of these results, we believe that detection of high-risk ECG factors (eg, QTc prolongation, ischemia/infarction) should mandate evaluation of a serum cardiac troponin as part of the initial ED evaluation of acute drug overdose.

Previously, use of QRS prolongation and  $R_{avR}$  had been utilized to risk stratify for seizures and dysrhythmia limited only to patients with tricyclic antidepressant poisoning.<sup>9,20,21</sup> Because the present study utilized a patient population with a low (<5%) rate of tricyclic antidepressant use, and different composite study outcome (ie, ACVE), it is not surprising that QRS parameters performed differently in this study. Similar to our prior derivation study,<sup>5</sup>  $R_{avR}$  was not associated with ACVE in our population. However, this validation study was able to detect an association between the QRS interval and ACVE (Table 2). It should be noted that QTc vastly outperformed QRS for prediction of the study outcome. Therefore, QTc should be used preferentially over QRS for the ACVE risk stratification of acute overdose patients. However, these data should in no way dissuade practitioners from the traditional application of QRS cut points and  $R_{avR}$  to risk-stratify patients with known tricyclic toxicity.

In patients with cardiac disease, QTD predicts myocardial injury, sudden cardiac death, and adverse cardiac events in patients with Long QT Syndrome.<sup>12,22,23</sup> Malik and colleagues previously defined normal QTD values between 10 and 70 ms,<sup>13</sup> with abnormal QTD  $>100$  ms. However, QTD was previously evaluated in the drug overdose literature, finding a strong association with ACVE using a cutoff  $>50$  ms.<sup>5</sup> The current study therefore used the latter definition of severely prolonged QTD, and these results confirm those of the prior derivation study. However, we found that QTc outperformed QTD for ACVE prediction, both using receiver operating characteristics analysis as well as diagnostic test characteristics (eg, sensitivity, specificity). Therefore, given the superiority and ease of use of the QTc, we do not recommend routine calculation of the QTD for patients with acute drug overdose. Further studies evaluating QTD for acute drug poisoning do not appear to be warranted.

In order to calculate the QTD, we measured the raw QT using the threshold method (ie, the intersection point of the descending T-wave and the isoelectric line), as opposed to the tangent method (ie, the intersection of the isoelectric line and a tangent line, fitted by least squares, over the descending slope of the T-wave).<sup>24</sup> Some data exist indicating there is higher reproducibility of the threshold method over the tangent method.<sup>25</sup> To the best of our knowledge, there is no universally accepted standard for QT measurement in the

context of calculating QTD; we have therefore used the threshold method based on prior work from our group,<sup>5</sup> and from others.<sup>26,27</sup>

## Limitations

Because of regional differences in drugs of abuse, the ACVE rates in other settings may not be similar to those found in this study. Real-time cardiologist interpretation of ischemia or infarction in clinical practice may not be possible in the majority of settings; however, emergency physicians are generally proficient at interpreting ECGs for ischemia/infarction,<sup>18</sup> and furthermore the best predictor (ie, QTc  $\geq$ 500 ms) was computer generated. This study used computer-generated Bazett's formula for QT correction, rather than more accurate manual measurement with linear correction formulae,<sup>24,25,28,29</sup> to enhance this study's generalizability given that Bazett's is still the most widely used QTc formula. We acknowledge that this may have slightly limited the accuracy of the QTc data; however, we anticipate that this may have improved the real-world applicability of our results. It is difficult to assign causality for ACVE to a single drug, especially in multidrug exposures; therefore, this underscores the utility of objective ECG findings, rather than reliance on drug concentrations, as part of the initial risk stratification to predict ACVE in patients with acute drug overdose. In addition, the estimates of effect, such as the OR, were not very precise with 95% CIs ranging from 4 to 27.

## Conclusions

This study confirms that the ECG is an essential tool for evaluation of the cardiovascular prognosis and medical clearance of all ED patients with acute drug overdose. Furthermore, this study validates previously derived high-risk features of the admission ECG (ectopy, QTc prolongation, nonsinus rhythm, and ischemia/infarction) to risk stratify for ACVE in this patient population.

## Sources of Funding

This study was funded at least in part by grant DA026476 (PI: Manini) from the National Institutes of Health (NIH). Manini is currently supported by NIH grant DA037317. Vedanthan is supported by the Fogarty International Center of the NIH under grant K01TW009218. Views expressed are our own and do not represent those of the NIH.

## Disclosures

None.

## References

- Centers for Disease Control and Prevention. Wide-ranging Online Data for Epidemiologic Research (WONDER Database). Atlanta, GA: US Department of Health and Human Services, CDC; 2010. Available at wonder.cdc.gov. Accessed March 30, 2016.
- Warner M, Chen L, Makuc D. Increase in fatal poisonings involving opioid analgesics in the USA, 1999–2006. NCHS data brief. Hyattsville, MD: National Center for Health Statistics; 2009. Available at www.cdc.gov. Accessed March 30, 2016.
- Manini AF, Nelson LS, Stimmel B, Vlahov D, Hoffman RS. Incidence of adverse cardiovascular events in adults following drug overdose. *Acad Emerg Med.* 2012;19:843–849.
- Warner M, Chen LH, Makuc DM, Anderson RN, Miniño AM. Drug poisoning deaths in the USA, 1980–2008. NCHS data brief, no 81. Hyattsville, MD: National Center for Health Statistics; 2011.
- Manini AF, Nelson LS, Skolnick AH, Slater W, Hoffman RS. Electrocardiographic predictors of adverse cardiovascular events in suspected poisoning. *J Med Toxicol.* 2010;6:106–115.
- Manini AF, Yates C. Utility of the electrocardiogram in drug overdose and poisoning: theoretical considerations and clinical implications. *Curr Cardiol Rev.* 2012;8:137–151.
- Manini AF, Hoffman RS, Stimmel B, Vlahov D. Clinical risk factors for in-hospital adverse cardiovascular events after acute drug overdose. *Acad Emerg Med.* 2015;22:499–507.
- Gilbert EH, Lowenstein SR, Koziol-McLain J, Barta D, Steiner J. Chart reviews in emergency medicine research: where are the methods? *Ann Emerg Med.* 1996;27:305–308.
- Liebelt EL, Francis PD, Wolf AD. ECG lead aVR versus QRS interval in predicting seizures and arrhythmias in acute tricyclic antidepressant toxicity. *Ann Emerg Med.* 1995;26:195–201.
- Committee for Proprietary Medicinal Products. *The Assessment of the Potential for QT Interval Prolongation by Non-Cardiovascular Medicinal Products.* London: Committee for Proprietary Medicinal Products; 1997.
- Kenigsberg DN, Khanal S, Kowalski M, Krishnan SC. Prolongation of the QTc interval is seen uniformly during early transmural ischemia. *J Am Coll Cardiol.* 2007;49:1299–1305.
- Calder K, Tomongin C, Mallon WK, Genna T, Bretsky P, Henderson SO. Manual measurement of QT dispersion in patients with acute myocardial infarction and nondiagnostic electrocardiograms. *Acad Emerg Med.* 2002;9:851–854.
- Malik M, Batchvarov VN. Measurement, interpretation and clinical potential of QT dispersion. *J Am Coll Cardiol.* 2000;36:1749–1766.
- Vanden Hoek TL, Morrison LJ, Shuster M, Donnino M, Sinz E, Lavonas EJ, Jeejeebhoy FM, Gabrielli A. Part 12: cardiac arrest in special situations: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. *Circulation.* 2010;122:S829–S861.
- Sayre MR, Koster RW, Botha M; on behalf of the Adult Basic Life Support Chapter Collaborators. Part 5: adult basic life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation.* 2010;122:S298–S324.
- Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Writing Group on Behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. *J Am Coll Cardiol.* 2012;60:1581–1598.
- Gaze DC, Collinson PO. Cardiac troponins as biomarkers of drug- and toxin-induced cardiac toxicity and cardiac protection. *Expert Opin Drug Metab Toxicol.* 2005;1:715–725.
- Eken C, Goksu E, Eray O, Yalcinkaya S. The consistency of emergency physicians' and cardiologists' ECG interpretation and likelihood classification of chest pain patients. *Int J Clin Pract.* 2006;60:1194–1197.
- Manini AF, Stimmel B, Hoffman RS, Vlahov D. Utility of cardiac troponin to predict drug overdose mortality. *Cardiovasc Toxicol.* 2016;16:355–360.
- Boehnert MT, Lovejoy FH Jr. Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants. *N Engl J Med.* 1985;313:474–479.
- Niemann JT, Bessen HA, Rothstein RJ, Laks MM. Electrocardiographic criteria for tricyclic antidepressant cardiotoxicity. *Am J Cardiol.* 1986;57:1154–1159.
- Darbar D, Luck J, Davidson N, Pringle T, Main G, McNeill G, Struthers AD. Sensitivity and specificity of QTc dispersion for identification of risk of cardiac death in patients with peripheral vascular disease. *BMJ.* 1996;312:874–878.
- Sauer AJ, Moss AJ, McNitt S, Peterson DR, Zareba W, Robinson JL, Qi M, Goldenberg I, Hobbs JB, Ackerman MJ, Benhorin J, Hall WJ, Kaufman ES,

- Locati EH, Napolitano C, Priori SG, Schwartz PJ, Towbin JA, Vincent GM, Zhang L. Long QT syndrome in adults. *J Am Coll Cardiol*. 2007;49:329–337.
24. McLaughlin NB, Campbell RW, Murray A. Comparison of automatic QT measurement techniques in the normal 12 lead electrocardiogram. *Br Heart J*. 1995;74:84–89.
25. Sharif H, O'Leary D, Ditor D. Comparison of QT-interval and variability index methodologies in individuals with spinal cord injury. *Spinal Cord*. 2016. doi: 10.1038/sc.2016.118. Available at: <http://www.nature.com/sc/journal/vol/54/issue/11/1038-sc2016118a.html>. Accessed January 19, 2016.
26. Priori SG, Napolitano C, Diehl L, Schwartz PJ. Dispersion of the QT interval: a marker of therapeutic efficacy in the idiopathic long QT syndrome. *Circulation*. 1994;89:1681–1689.
27. Veglio M, Bruno G, Borra M, Macchia G, Bargerò G, D'Errico N, Pagano GF, Cavallo-Perin P. Prevalence of increased QT interval duration and dispersion in type 2 diabetic patients and its relationship with coronary heart disease: a population-based cohort. *J Intern Med*. 2002;251:317–324.
28. Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is "normal". *J Cardiovasc Electrophysiol*. 2006;17:333–336.
29. Rautaharju PM, Surawicz B, Gettes LS. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. *J Am Coll Cardiol*. 2009;53:982–991.